期刊文献+

羟基喜树碱联合奥沙利铂诱导人大肠癌耐药细胞株LoVo/5-FU的凋亡机制 被引量:3

Combination of Hydroxycamptothecine with oxaliplatin in induction of drug-resistant colorectal cancer cell line LoVo/5-FU and mechanism of apoptosis
原文传递
导出
摘要 目的:体外观察羟基喜树碱(HCPT)联合奥沙利铂(L-OHP)对人大肠癌耐药细胞株LoVo/5-FU增殖抑制及诱导凋亡作用,并初步探讨其诱导凋亡方面机制。方法:MTT法测定HCPT联合L-OHP对LoVo/5-FU细胞增殖抑制作用,并根据中效原理判断两药合用时的效应。流式细胞仪观察两药对LoVo/5-FU细胞的凋亡诱导作用。半定量RT-PCR方法检测单药及联合作用后X染色体连锁的凋亡抑制蛋白(XIAP)mRNA表达变化。结果:HCPT联合L-OHP对LoVo/5-FU细胞有明显的抑制增殖作用,细胞增殖的抑制率与药物浓度呈正相关。在抑制率(fa)>0.18时合用指数(CI)<1,两药表现为协同作用。HCPT浓度分别为0.02、0.04和0.08 mg/L。作用48 h后,LoVo/5-FU细胞凋亡率分别为5.92±0.58、9.93±0.62和3.76±0.45。当0.04 mg/L HCPT联合L-OHP作用48 h后,其凋亡率为18.44±0.57,联合组与单药组比较差异有统计学意义,P<0.05。耐药细胞LoVo/5-FU较亲本细胞LoVo高表达XIAP mRNA(0.88±0.03vs0.11±0.02,P<0.01),两药联合作用后XIAP mRNA降低明显为0.21±0.03,P<0.01。结论:HCPT联合L-OHP能够协同抑制LoVo/5-FU细胞增殖,其机制可能与诱导细胞凋亡有关,抑制XIAP表达发挥作用。 OBJECTIVE: To investigate the possible mechanism of proliferation inhibition and apoptosis induced by hydroxycamptothecine(HCPT) and oxaliplatin(L-OHP) on cell line LoVo/5-FU in vitro.METHODS: Proliferation inhibition induced by HCPT and L-OHP on cell line LoVo/5-FU was tested by MTT method.Flow cytometry observed the role of HCPT as a single drug and in combination with L-OHP to induce the apoptosis in LoVo/5-FU cell line.Semi quantitative RT-PCR test was done to determine the expression of mRNA of X-linked inhibitor of apoptosis protein(XIAP) in LoVo/5-FU and LoVo cells after using HCPT and L-OHP as individual drug and in combination.RESULTS:HCPT combined with L-OHP significantly inhibited LoVo/5-FU cell proliferation,cell proliferation inhibition rate was positively correlatedwith drug concentration.When fa〉0.18,CI1,the two drugs showed synergy.When HCPT concentrations were 0.02,0.04 and 0.08 mg/L,the apoptosis rates of LoVo/5-FU cells were 5.92±0.58,9.93±0.62,3.76±0.45 after 48 h.Use concentration of HCPT 0.04 mg/L combined with L-OHP,the apoptosis rate were 18.44±0.57.Single drug groups vs combination group was statistically significant(P0.05).Compared with LoVo,the LoVo/5-FU had high expression of XIAP mRNA((0.88±0.03) vs(0.11±0.02),P〈0.01),two drugs combined significantly reduced XIAP mRNA for 0.21±0.03(P〈0.01).CONCLUSION: HCPT combined with L-OHP can actedsynergistically inhibit the cell proliferation of LoVo/5-FU cell line,which may be related to inhibit the expression of XIAP,thus inducing apoptosis.
出处 《中华肿瘤防治杂志》 CAS 2011年第3期183-186,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 抗肿瘤药 肠肿瘤 药物协同作用 细胞凋亡 antineoplastic agents intestinal neoplasms drug synergism apoptosis
  • 引文网络
  • 相关文献

参考文献11

  • 1Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study[J]. J Clin Oncol, 2004, 22 (2): 229-237.
  • 2Yao Y, Zhao H, Sun Y J , et al. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer[J]. Tohoku J Exp Med, 2008, 215(3) : 267-278.
  • 3Chou T C, Motzer R J, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design[J]. J Natl Cancer Inst, 1994,86(20):1517-1524.
  • 4Chou T C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme in hibitors[J]. Adv Enzyme Regul, 1984,22: 27-55.
  • 5Demarquay D, Huchet M, Coulomb H, et al. BN80927: a novel ho moeamptothecin that inhibits proliferation of human tumor cells in vitro and in vivoc[J]. Cancer Res, 2004, 64(14):4942-4949.
  • 6宋恕平.结直肠癌的内科治疗及进展[J].中华肿瘤防治杂志,2006,13(14):1041-1042. 被引量:15
  • 7顾建春,郑磊贞,陈强.羟基喜树碱联合奥沙利铂对人肺癌细胞作用的体外研究[J].现代肿瘤医学,2009,17(2):206-208. 被引量:5
  • 8赵晖,陶钧,孙元珏,薛鹏,姚阳.羟基喜树碱联合草酸铂方案对人大肠癌细胞作用的研究[J].肿瘤,2005,25(5):416-419. 被引量:10
  • 9孙元珏,赵晖,郭跃武,林峰,蔡讯,唐晓春,姚阳.羟基喜树碱联合草酸铂治疗晚期消化道肿瘤的临床疗效[J].中华肿瘤杂志,2004,26(12):749-752. 被引量:13
  • 10La Casse E C, Mahoney D J, Cheung H H, et al. IAP-targeted therapies for cancer[J]. Oneogene, 2008,27 : 6252-6275.

二级参考文献22

  • 1孙元珏,赵晖,郭跃武,林峰,蔡讯,唐晓春,姚阳.羟基喜树碱联合草酸铂治疗晚期消化道肿瘤的临床疗效[J].中华肿瘤杂志,2004,26(12):749-752. 被引量:13
  • 2顾建春,郑磊贞,陈强.羟基喜树碱在进展期非小细胞肺癌中的应用[J].中国肿瘤临床与康复,2006,13(5):475-477. 被引量:1
  • 3Chou TC, Motzer R J, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design [ J ]. J Natl Cancer Inst, 1994,86 (20) : 1517 - 1524.
  • 4Chou TC, Talalay P. Quantitative analysis of dose - effect relationships: the combined effects of muhiple drugs or enzyme inhibitors [J]. Adv Enzyme Regul, 1984,22:27 -55.
  • 55 Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB - 506 and SN - 38, in human small cell lung cancer ceils [ J ]. Cancer Res, 1996,56 (4) :789 -793.
  • 6Goldwasser F, Bozec L, Zeghari - Squalli N, et al. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV - 1 human ovarian cancer cell line[J]. Anticancer Drugs, 1999,10(2) :195 -201.
  • 7Zeghari - Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase Ⅰ inhibitor SN -38 and the diaminocyclohexane platinum derivative oxaliplatin[J]. Clin Cancer Res, 1999,5(5) :1189 - 1196.
  • 8Guichard S, Amould S, Hennebelle I, et al. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo [J]. Anticancer Drugs, 2001,12 (9) :741 - 751.
  • 9Kanzawa F, Koizumi F, Koh Y, et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase Ⅰ inhibitor irinotecan and the mechanism of this interaction[J]. Clin Cancer Res, 2001,7( 1 ) :202 -209.
  • 10Goldwasser F, Shimizu T, Jackman J, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells [ J ]. Cancer Res, 1996,56 ( 19 ) : 4430 - 4437.

共引文献38

同被引文献32

  • 1刘仁刚,罗贤雯,周洁萍,刘云华,骆清铭.高温对HeLa细胞周期及周期因子Cyclin E和Cyclin A的影响[J].中华物理医学与康复杂志,2004,26(12):719-722. 被引量:3
  • 2冯俊奇,李秀兰,白人骁.细胞凋亡机制研究进展[J].国际生物医学工程杂志,2006,29(1):45-47. 被引量:12
  • 3Mahteme H,Pahlman L. Treatment of peritoneal surface malignancy by peritonectomy and intraperitoneal chemotherapy:a novel therapy with curative potential [J]. Minerva Chir, 2005, 60(3) : 151-157.
  • 4Smeenk RM, Verwaal VJ,zoetlnulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritoneia report of 103 proeedures[J]. Eur J Surg Oncol,2006,32(6): 186-190.
  • 5Almquist KC, Loe DW, Hipfer DR,et al. Characterization of the Mr190,000 multidrug resistance protein (MRP) in drug-selected and tramsfected human tumor cell[J]. Cancer Res, 1999,55 (1): 102-110.
  • 6Sentrnan CL, Shutter JR, Hockenbery D, et al. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes[J]. Cell, 1991,67(5):879-888.
  • 7Kataoka S,Naito M,Tomida A,et al. Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia a U937 cells[J]. Exp Cell Res,1994,4(2):215-199.
  • 8吴稚冰,马胜林,陈雪琴,等.伊榄香烯联合高温对肺腺癌A549细胞作用的实验研究[J].中华中医药学,2012,30(4):742-744.
  • 9Guenova ML,Balatzenko GN, Nikolova VR, et ai. An anti-apoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs,Bcl-2,Survivin and MDR1 gene[J]. Hematology,2010,15(3): 135-143.
  • 10Atallah D, Marsaud V, Radanyi C, et aI. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle proliferation in human carcinoma cell lines [J]. Int J Hyperthermia,2004,20(4) :405-419.

引证文献3

二级引证文献1

;
使用帮助 返回顶部